Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/1999

01-06-1999 | Commentary

Cytokines and direct cell contact in synovitis: relevance to therapeutic intervention

Authors: Jean-Michel Dayer, Danielle Burger

Published in: Arthritis Research & Therapy | Issue 1/1999

Login to get access

Excerpt

In chronic inflammation, which leads to tissue destruction and fibrosis, immunocompetent cells migrate through the vascular endothelium to the target tissue. A prototype of these events is synovitis, which occurs in diseases such as rheumatoid arthritis. The hypothesis that cells from the bone marrow could also migrate directly to the synovium through channels interconnecting the two compartments is still under debate. Also, there is no definitive answer regarding the number of cells that result from infiltration of the synovium after migration, or from proliferation at the local site. Furthermore, the survival of the cells in synovitis is being subjected to some scrutiny, because there is some evidence for a lack of apoptosis in pathological conditions. …
Literature
1.
Dayer J-M, Arend WP: Cytokines and growth factors. In:Textbook of Rheumatology, 5th ed. Edited by Kelley WN, Harris ED, Ruddy S, Sledge CB. Philadelphia: WB Saunders,. 1997, 267-286.
2.
Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996, 14: 397-440. 10.1146/annurev.immunol.14.1.397.PubMedCrossRef
3.
McInnes IB, Liew FY: Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today. 1998, 19: 75-79. 10.1016/S0167-5699(97)01205-X.PubMedCrossRef
4.
Klimiuk PA, Goronzy JJ, Weyand CM: Interleukin-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol. 1999, 162: 4293-4299.PubMed
5.
Chabaud M, Durand JM, Buchs N, et al: Human interleukin-17. Arthritis Rheum. 1999, 42: 963-970. 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E.PubMedCrossRef
6.
Kotake S, Udagawa N, Takahashi N, et al: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999, 103: 1345-1352.PubMedPubMedCentralCrossRef
7.
Gracie JA, Forsey RJ, Chan WL, et al: A pro-inflammatory role for interleukin-18 in rheumatoid arthritis. J Clin Invest. 1999
8.
Udagawa N, Horwood NJ, Elliott J, et al: Interleukin-18 (interferongamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med. 1997, 185: 1005-1012. 10.1084/jem.185.6.1005.PubMedPubMedCentralCrossRef
9.
Burger D, Dayer J-M: Interactions between T cell plasma membranes and monocytes. In:T Cells in Arthritis. Edited by Miossec P, van den Berg WB, Firestein GS. Basel: Birkhä. 1998, : 111-128.
10.
Loetscher P, Uguccioni M, Bordoli L, et al: CCR5 is characteristic of Th1 lymphocytes. Nature. 1998, 391: 344-345. 10.1038/34814.PubMedCrossRef
11.
Probert L, Akassoglou K, Alexopoulou L, et al: Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukoc Biol. 1996, 59: 518-525.PubMed
12.
Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 1996, 39: 115-124.PubMedCrossRef
13.
Woolley DE, Tetlow LC: Mast cells and proinflammatory cytokines in the rheumatoid lesion. Arthritis Res.
14.
Korganow A-S, Ji H, Mangialaio S, et al: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999, 10: 451-461.PubMedCrossRef
15.
Vey E, Zhang J-H, Dayer J-M: IFN-γ and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression,cytokine production, and responsiveness to contact with activated T cells. J Immunol. 1992, 149: 2040-2046.PubMed
16.
Isler P, Vey E, Zhang J-H, Dayer J-M: Cell surface glycoproteins expressed on activated human T cells induce production of inter-leukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw . 1993, 4: 15-23.PubMed
17.
Sebbag M, Parry SL, Brennan FM, Feldmann M: Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumour necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol. 1997, 27: 624-632.PubMedCrossRef
18.
Malik N, Greenfield BW, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996, 156: 3952-3960.PubMed
19.
Wagner DH, Stout RD, Suttles J: Role of the CD40-CD40 ligand interaction in CD4(+) T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol. 1994, 24: 3148-3154.PubMedCrossRef
20.
Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA: Impaired T cellmediated macrophage activation in CD40 ligand-deficient mice. J Immunol. 1996, 156: 8-11.PubMed
21.
MacDonnald KPA, Nishioka Y, Lipsky PE, Thomas R: Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest. 1997, 100: 2404-2414.CrossRef
22.
Yellin MJ, Brett J, Baum D, et al: Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. J Exp Med. 1995, 182: 1857-1864.PubMedCrossRef
23.
Armand M, Ishihara H, Rubio M, Delespesse G, Sarfati M: Soluble CD23 directly activates monocytes to contribute to the antigen-independent stimulation of resting T cells. J Immunol. 1995, 155: 4868-4875.
24.
McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY: Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor alpha production in rheumatoid arthritis. Nature Med. 1997, 3: 189-195.PubMedCrossRef
25.
Chizzolini C, Chicheportiche R, Burger D, Dayer JM: Human Th1 cells preferentially induce interleukin (IL)-1 beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol. 1997, 27: 171-177.PubMedCrossRef
26.
Burger D, Rezzonico R, Li J-M, et al: Imbalance between interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum. 1998, 41: 1748-1759. 10.1002/1529-0131(199810)41:10<1748::AID-ART7>3.3.CO;2-V.PubMedCrossRef
Metadata
Title
Cytokines and direct cell contact in synovitis: relevance to therapeutic intervention
Authors
Jean-Michel Dayer
Danielle Burger
Publication date
01-06-1999
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/1999
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar5

Other articles of this Issue 1/1999

Arthritis Research & Therapy 1/1999 Go to the issue

Review

Genetics of rheumatoid arthritis: confronting complexity

Paper Report

HLA, killer cell inhibitory receptors and autoimmune anemia

Review

The challenge of early synovitis: multiple pathways to a common clinical syndrome

Research article

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis

Paper Report

Functional heterogeneity of osteoclasts

Paper Report

VEGF and bone resorption by osteoclasts
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits